NOVONIX (NVX) director Jean Oelwang holds 195,938 share rights

Rhea-AI Filing Summary

NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Oelwang Jean

Role null

Type	Security	Shares	Price	Value
holding	Share rights	--	--	--

Holdings After Transaction: Share rights — 195,938 shares (Direct, null)

Footnotes (1)

Key Figures

Share rights held: 195,938 share rights Underlying ordinary shares: 195,938 shares Exercise price: $0.0000 per share +1 more

4 metrics

Share rights held 195,938 share rights Total share rights following transaction

Underlying ordinary shares 195,938 shares Underlying security linked to share rights

Exercise price $0.0000 per share Exercise price for share rights

Expiration date December 31, 2027 Expiration of share rights

Key Terms

Share rights, Ordinary shares, Exercise price, Expiration date

4 terms

Share rights financial

"security_title: "Share rights" and derivativeSummary "Share rights""

Ordinary shares financial

"underlying_security_title: "Ordinary shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Exercise price financial

"conversion_or_exercise_price: "0.0000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Expiration date financial

"expiration_date: "2027-12-31T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oelwang Jean

(Last) (First) (Middle)

1029 WEST 19TH STREET

(Street)

CHATTANOOGA TENNESSEE 37408

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NOVONIX Ltd [ NVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share rights	$0							12/31/2026	12/31/2027	Ordinary shares	195,938		195,938	D

Explanation of Responses:

	Suzanne Yeates	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider position did NOVONIX (NVX) director Jean Oelwang report?

Jean Oelwang reported holding 195,938 share rights linked to NOVONIX ordinary shares. These are derivative securities that can convert into the same number of underlying ordinary shares, according to the Form 4 data provided.

Did Jean Oelwang buy or sell NOVONIX (NVX) shares in this Form 4?

The Form 4 does not show any explicit buy or sell transactions. It records a holding entry for share rights with an unknown transaction code, indicating position details rather than a clear purchase or sale.

What are the key terms of Jean Oelwang’s NOVONIX (NVX) share rights?

The share rights have an exercise price of $0.0000 and an expiration date of December 31, 2027. They relate to 195,938 underlying ordinary shares, all held as a direct ownership position in the filing.

How many NOVONIX (NVX) securities does Jean Oelwang hold after this Form 4 entry?

After the reported holding entry, Jean Oelwang is shown with 195,938 share rights, corresponding to 195,938 underlying ordinary shares. This figure reflects the total derivative position following the reported transaction.

Is Jean Oelwang’s NOVONIX (NVX) position direct or indirect in this filing?

The Form 4 characterizes the position as direct ownership, using the ownership code “D.” This means the 195,938 share rights and corresponding underlying ordinary shares are reported as directly held by Jean Oelwang.